|Source:||Evaluate Ltd, Drugs@FDA|
|Report Date||Thursday, September 10, 2015|
|USA Sales (MEPS) - $m|
USA Prescription Volume (MEPS) - Vol
|Average Cost per Rx (US $)||No. of Rx per person|
|No Report Filters Set|
Medical Expenditure Panel Survey (MEPS) as a Primary Care Data Source
Overview of Medical Expenditure Panel Survey (MEPS)
The annual Medical Expenditure Panel Survey, of approximately 13,000 families and 35,000 individuals, includes a representative survey of the consumption of prescription medicines in the USA, analysing approx. 350,000 prescriptions dispensed each year. The survey results have been scaled-up to provide an estimate of total pharmaceutical drug consumption, retail sales, prescription volume and number of persons taking the drug, in the USA. The focus of the survey is primary care dispensing of prescriptions and does not cover hospital prescribed drugs. The survey is conducted and published each year by AHRQ (Agency for Healthcare Research and Quality), U.S. Department of Health & Human Services, in October.
Survey Publishing Dates:
2013: Released August 2015
2014: Expected to be released August 2016
USA Retail Sales, Prescription Volume & Actual Prices (2005-13) on:
· 32,000 Packs Level Sales (standardised to National Drug Code)
· 5,000 Product Level Sales; Including primary care generics (standardised to FDA Application number & EvaluatePharma Product/ Generic Name)
· USA Retail Sales by Indication (standardised to ICD-9 Code)
· 2.1 million Prescription Drug Prices Analyzed
· Data standardised to EvaluatePharma Product/ Generic Names/ EphMRA/ Pharma Class/ Indications
Highlights of 2013 Survey
· USA Retail Primary Care Prescription Sales: $238bn
o of which USA Retail Generic Sales: $79bn
· 76% of USA Retail Prescription filled by Generics; Up from 71% in 2012
Scaling-up MEPS Observations and Interpretation of MEPS data
Each person in the survey is weighted according to the person’s representation in the USA (by census region, metropolitan statistical area (MSA) status, race/ethnicity, sex and age). The total of the person-level weights for all of the participant in the survey will therefore be equal to the USA population for the year in question. Each analysis carried out is then scaled up by multiplying by this person-level weight. Each prescription event in the survey is multiplied by the person level weight to provide a national estimate for the volume and retail value, of that prescription event. The total of this person-level weight will therefore produce a national estimate of total prescription volume and retail value.
The prescription cost reported is the retail price the patient paid for the prescription, and will include the pharmacy and wholesaler mark up costs, it does not include any payer rebate.
Note on Raw MEPS Data:
The MEPS survey includes certain prescription medical devices such as diabetes monitoring devices; the analysis of the total USA primary care prescription market excludes these sales as each prescription event has been mapped to drug packs (NDC) & FDA application (Drugs@FDA) datasets to allow analysis at a pack and product level.